Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD)
ASX:RMD
Want to see AU:RMD full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.4Last Year’s EPS
0.35Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive operating and financial picture: healthy revenue growth (11% headline, 8% constant currency), strong gross margin expansion (+290 bps YoY), double-digit EPS growth (~21%), robust free cash flow and continued share repurchases/dividends. Strategic highlights include successful mask innovations with measurable adherence gains (AirTouch N30i +6% 90-day compliance), continued AirSense 11 rollouts, clinical education traction, favorable GLP-1-related demand signals, and the tuck-in acquisition of Noctrix to expand into RLS. Noted challenges include rising SG&A and R&D spend, component/fuel cost pressures, a $10M minority investment write-down, modest near-term EPS dilution from Noctrix, and reimbursement/channel variability that could constrain adoption in pockets. Overall, positives around margin expansion, cash generation, product adoption, and long-term strategic positioning outweigh the identified headwinds.Company Guidance
Revenue Growth
Group revenue of $1.43 billion, up 11% headline and 8% on a constant currency basis versus prior year; Americas devices +6% and masks/other +12% globally (masks/other +14% in Americas excluding VertuOx).
Gross Margin Expansion
Gross margin of 62.8%, increasing 290 basis points year-over-year and 50 basis points sequentially, driven by component cost improvements, manufacturing and logistics efficiencies, and favorable product mix/currency.
Earnings and Operating Profit
Non-GAAP diluted earnings per share increased ~21%; operating profit rose 18% year-over-year and operating margin improved to 36.7% from 34.4%.
Strong Free Cash Flow and Balance Sheet
Reported $520 million free cash flow in the quarter (management also cited $554 million cash from operations), above 100% free cash flow conversion; cash balance $1.7 billion, gross debt $664 million, net cash ~$996 million.
Shareholder Returns
Returned $262 million to shareholders in the quarter via dividends and $175 million of share repurchases (approximately 673k shares); Board declared quarterly dividend of $0.60 per share; plan to repurchase at least $175 million in 2026.
Mask Portfolio Momentum & Clinical Impact
Strong adoption of fabric-based masks (AirTouch N30i, F30i Comfort, F30i Clear); real-world data show AirTouch N30i delivers 6% higher 90-day compliance versus silicone equivalent (600 basis points), supporting higher lifetime value from improved adherence.
Device Rollouts and Market Expansion
Continued global rollout of AirSense 11 platform including Latin America and recent launch in China; devices grew ~6% on a constant currency basis.
Clinical Education and Research Traction
CME programs completed >80,000 times by >45,000 unique clinicians with 78% indicating intent to change practice; company tracking growing evidence linking OSA treatment to reduced dementia and Parkinson's risk, supporting broader clinical relevance.
GLP-1 Related Demand Tailwind
Real-world analyses: among n=1.7M patients, PAP patients who start GLP-1 show 2-year resupply +5.1% and 3-year resupply +6.2%; claims analysis of n=2.1M shows patients with scripts for both PAP and GLP-1 are 11% more likely to start PAP and >3% more likely to have a resupply at one year and >6% at three years — positioning GLP-1s as a demand-generation tailwind.
Strategic Acquisition (Noctrix)
Signed agreement to acquire Noctrix Health for $340 million (expected close ~June 1, 2026); Noctrix run-rate revenue ~$24 million annually, reportedly growing faster and with higher gross margins, expanding portfolio into restless leg syndrome (RLS).
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) Earnings, Revenues Date & History
AU:RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:RMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | AU$29.69 | AU$28.64 | -3.52% |
Jan 29, 2026 | AU$36.21 | AU$37.34 | +3.13% |
Oct 30, 2025 | AU$38.60 | AU$39.23 | +1.65% |
Jul 31, 2025 | AU$42.04 | AU$42.47 | +1.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) report earnings?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock?
The P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is N/A.
What is AU:RMD EPS forecast?
AU:RMD EPS forecast for the fiscal quarter 2026 (Q4) is 0.4.